Abstract
Background: Alzheimer’s disease is one of the most common mental illnesses. It is posited that more than 25% of the population is affected by some mental disease during their lifetime. Treatment of each patient draws resources from the economy concerned. Therefore, it is important to quantify the potential economic impact.
Methods: Agent-based, system dynamics and numerical approaches to dynamic modeling of the population of the European Union and its patients with Alzheimer’s disease are presented in this article. Simulations, their characteristics, and the results from different modeling tools are compared.
Results: The results of these approaches are compared with EU population growth predictions from the statistical office of the EU by Eurostat. The methodology of a creation of the models is described and all three modeling approaches are compared. The suitability of each modeling approach for the population modeling is discussed.
Conclusion: In this case study, all three approaches gave us the results corresponding with the EU population prediction. Moreover, we were able to predict the number of patients with AD and, based on the modeling method, we were also able to monitor different characteristics of the population.
Keywords: Alzheimer’s disease, population modeling, system dynamics, agent-based model, numerical model, population prediction.
Current Alzheimer Research
Title:Numeric, Agent-based or System Dynamics Model? Which Modeling Approach is the Best for Vast Population Simulation?
Volume: 15 Issue: 8
Author(s): Richard Cimler*, Hana Tomaskova, Jitka Kuhnova, Ondrej Dolezal, Pavel Pscheidl and Kamil Kuca
Affiliation:
- Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, Hradec Kralove,Czech Republic
Keywords: Alzheimer’s disease, population modeling, system dynamics, agent-based model, numerical model, population prediction.
Abstract: Background: Alzheimer’s disease is one of the most common mental illnesses. It is posited that more than 25% of the population is affected by some mental disease during their lifetime. Treatment of each patient draws resources from the economy concerned. Therefore, it is important to quantify the potential economic impact.
Methods: Agent-based, system dynamics and numerical approaches to dynamic modeling of the population of the European Union and its patients with Alzheimer’s disease are presented in this article. Simulations, their characteristics, and the results from different modeling tools are compared.
Results: The results of these approaches are compared with EU population growth predictions from the statistical office of the EU by Eurostat. The methodology of a creation of the models is described and all three modeling approaches are compared. The suitability of each modeling approach for the population modeling is discussed.
Conclusion: In this case study, all three approaches gave us the results corresponding with the EU population prediction. Moreover, we were able to predict the number of patients with AD and, based on the modeling method, we were also able to monitor different characteristics of the population.
Export Options
About this article
Cite this article as:
Cimler Richard*, Tomaskova Hana , Kuhnova Jitka , Dolezal Ondrej , Pscheidl Pavel and Kuca Kamil, Numeric, Agent-based or System Dynamics Model? Which Modeling Approach is the Best for Vast Population Simulation?, Current Alzheimer Research 2018; 15 (8) . https://dx.doi.org/10.2174/1567205015666180202094551
DOI https://dx.doi.org/10.2174/1567205015666180202094551 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Superior Neuroprotective Effects of Cerebrolysin in Nanoparticle-Induced Exacerbation of Hyperthermia-Induced Brain Pathology
CNS & Neurological Disorders - Drug Targets The Role of P-Glycoprotein in Psychiatric Disorders: A Reliable Guard of the Brain?
Central Nervous System Agents in Medicinal Chemistry The Association of ACT -17 A/T Polymorphism with Alzheimer’s Disease: A Meta-Analysis
Current Alzheimer Research Subject Index To Volume 4
Current HIV Research Phosphodiesterase-4 Modulation as a Potential Therapeutic for Cognitive Loss in Pathological and Non-Pathological Aging: Possibilities and Pitfalls
Current Pharmaceutical Design A Perspective to the Correlation Between Brain Insulin Resistance and Alzheimer: Medicinal Chemistry Approach
Current Diabetes Reviews Hypothermia and Alzheimer's Disease Neuropathogenic Pathways
Current Alzheimer Research Maternal Vitamin D Status and Development of Asthma and Allergy in Early Childhood
Mini-Reviews in Medicinal Chemistry Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Editorial [Hot Topic:Sleep Medicine (Guest Editor: Salim Surani)]
Current Respiratory Medicine Reviews Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Current Pharmaceutical Design Editorial [ New Advances in Alzheimers Disease: From Biology to Therapy Guest Editor: Giuseppina Tesco ]
Current Genomics Early β-Amyloid-induced Synaptic Dysfunction Is Counteracted by Estrogen in Organotypic Hippocampal Cultures
Current Alzheimer Research State-of-the-Art Methodologies for the Discovery and Characterization of DNA G-Quadruplex Binders
Current Pharmaceutical Design Psychiatric Disorders Associated with FXTAS
Current Psychiatry Reviews The Association of MME microRNA Binding Site Polymorphism with the Risk of Late Onset Alzheimer’s Disease in Northern Han Chinese
Current Neurovascular Research Carnosine and Lung Disease
Current Medicinal Chemistry The Chemistry and Pharmacology of Tetrahydropyridines
Current Medicinal Chemistry New therapeutic effects of cilostazol in patients with ischemic disorders
Current Vascular Pharmacology Herbal Medicines for the Prevention and Treatment of Alzheimer's Disease
Current Pharmaceutical Design